Nitrosamines and related compounds continue to be a hot topic among regulatory agencies globally.
Regulators are asking drug product manufacturers to identify products at risk of N-nitrosamine formation or contamination, which could impact the pharmaceutical industry supply chain.
This webinar provided an update on regulatory expectations for assessing, testing and reporting of nitrosamines and/or their potential formation in drug products. In addition, the webinar included best practice strategies and examples for ongoing communication between excipient suppliers and users.